Consistent with the need to maintain TET function in order to avoid cancer, two clinical trials are leveraging vitamin C, which activates TET2 (Qi et al. 2020), in TET2 mutant hematologic malignancies (NCT03397173 and NCT03433781) (Fig. 2). This evidence concerns the gene TET2 and cancer.